Physician profile
John E Warren
NPI 1609868124
$6,618.62
in general payments reported to CMS, 2019-2025
15 companies · $1,844 in 2025
The $1,844 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,096 · 2020: $11.47 · 2021: $1,520 · 2022: $203 · 2023: $257 · 2024: $687 · 2025: $1,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,788.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $1,607.30 | 2025 | Optilight |
| Optovue, INC. | $1,250.00 | 2021 | |
| Alcon Vision LLC | $1,167.81 | 2019-2023 | Rocklatan, Rhopressa, Simbrinza |
| Sight Sciences, INC. | $1,050.00 | 2019 | |
| Visionix USA, INC | $539.28 | 2024 | Optical Coherence Tomography Hoct-1f |
| Coopervision INC. | $195.55 | 2021-2022 | |
| Astellas Pharma US INC | $135.00 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $124.99 | 2024 | Xdemvy |
| Kala Pharmaceuticals, INC. | $124.92 | 2021 | |
| Dompe US, INC. | $121.82 | 2025 | Oxervate |
| Glaukos Corporation | $115.30 | 2025 | Idosetr |
| Allergan, INC. | $115.00 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $26.16 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $22.98 | 2022 | |
| Sun Pharmaceutical Industries INC. | $22.51 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.